Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States. The company operates as a validator and super validator on the Canton Network, which provides validation and liveness services to the network. It also provides locking-as-a-service (LaaS) to Canton Network super validators and featured applications, which locks its own Canton Coin (CC) on a customer's behalf while retaining legal and beneficial ownership. In addition, the company invests in the Canton ecosystem. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is based in New York, New York.…
Canton Strategic Holdings’ Validator Scaling and LaaS Growth – Quarterly Update Report
Canton Strategic Holdings Plans Tokenized Trading of Its Own Shares on Canton Network
Canton Strategic Holdings (NASDAQ: CNTN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.210 USD on 20 November 2026, down 71.1% over 52 weeks. Its 52-week range is 1.190 USD to 5.830 USD: the price is 79.2% below the high and 1.7% above the low.
At a market capitalisation of 98.78M USD, it trades at 20.2 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 39% for CNTN.
Canton Strategic Holdings reports return on equity of -9.0%.
It holds more cash than debt, a net cash position of 26.92M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.